Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
